These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 9303508

  • 1. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Hathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J.
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [Abstract] [Full Text] [Related]

  • 2. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB, Hollinger FB.
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB, Fu XX, Tian GS, Xu DZ, Hao LJ, Huangfu YS, Su CX.
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [Abstract] [Full Text] [Related]

  • 4. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC, Bacon BR, Goldin RD.
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [Abstract] [Full Text] [Related]

  • 5. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group.
    Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, Everson GT, Hoefs JC, Fromm H, Black M, Foust RT, Pimstone NR, Heathcote EJ, Albert D.
    Am J Gastroenterol; 1999 Dec; 94(12):3583-8. PubMed ID: 10606323
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C.
    Hwang SJ, Lee SD, Chan CY, Lu RH, Chang FY.
    Am J Gastroenterol; 1999 Sep; 94(9):2496-500. PubMed ID: 10484014
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT, Jensen DM, Craig JR, van Leeuwen DJ, Bain VG, Ehrinpreis MN, Albert D, Joh T, Witt K.
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [Abstract] [Full Text] [Related]

  • 8. Consensus interferon: a novel interferon for the treatment of hepatitis C.
    Heathcote J.
    J Viral Hepat; 1998 Sep; 5 Suppl 1():13-8. PubMed ID: 9795924
    [Abstract] [Full Text] [Related]

  • 9. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group.
    Heathcote EJ, James S, Mullen KD, Hauser SC, Rosenblate H, Albert DG.
    Hepatology; 1999 Aug; 30(2):562-6. PubMed ID: 10421669
    [Abstract] [Full Text] [Related]

  • 10. Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group.
    Keeffe EB, Dusheiko GM, James SP, Mullen KD, Everson GT, Pimstone NR, Donovan J, Albert D.
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):207-10. PubMed ID: 10850384
    [Abstract] [Full Text] [Related]

  • 11. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, Voigt JJ, Selves J, Barange K, Puel J, Pascal JP.
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [Abstract] [Full Text] [Related]

  • 12. Treatment of chronic hepatitis C virus infection with recombinant consensus interferon.
    Tong MJ, Blatt LM, Resser KJ, Klein MC, Cruickshank SE, Figueroa T, Sayadzadeh K.
    J Interferon Cytokine Res; 1998 Feb; 18(2):81-6. PubMed ID: 9506458
    [Abstract] [Full Text] [Related]

  • 13. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS.
    Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
    [Abstract] [Full Text] [Related]

  • 14. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group.
    Keeffe EB, Dusheiko GM, Tong MJ, Hollinger FB, Heathcote EJ, McHutchison J, Albert D.
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):211-6. PubMed ID: 10850385
    [Abstract] [Full Text] [Related]

  • 15. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group.
    Pockros PJ, Tong M, Lee WM, van Leeuwen DJ, Keeffe EB, Bala K, Killenberg PG, Foust RT, Rosenblate HJ, Payne KM, Fromm H, Lesesne HR, Black M.
    J Viral Hepat; 1998 Jul; 5(4):271-6. PubMed ID: 9751014
    [Abstract] [Full Text] [Related]

  • 16. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, Grünewald K, Patsch J.
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [Abstract] [Full Text] [Related]

  • 17. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients.
    Manesis EK, Papaioannou C, Gioustozi A, Kafiri G, Koskinas J, Hadziyannis SJ.
    Hepatology; 1997 Sep; 26(3):734-9. PubMed ID: 9303505
    [Abstract] [Full Text] [Related]

  • 18. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T.
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [Abstract] [Full Text] [Related]

  • 19. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.
    Melian EB, Plosker GL.
    Drugs; 2001 Jun; 61(11):1661-91. PubMed ID: 11577799
    [Abstract] [Full Text] [Related]

  • 20. IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study.
    Tassopoulos NC, Vafiadis I, Tsantoulas D, Syrokosta J, Hatzis G, Delladetsima JK, Demonakou M, Sypsa V, Hatzakis AE.
    J Interferon Cytokine Res; 2002 Mar; 22(3):365-9. PubMed ID: 12034044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.